- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Economic Impact of IPF
The panel explores how IPF affects patient productivity and its contribution to the disease's overall economic burden.
EP: 1.Emerging Agents in IPF Treatment
EP: 2.IPF and PDE4B Inhibitors
EP: 3.Importance of Patient-Reported Outcomes
EP: 4.Future Possibilities in IPF Treatment
EP: 5.Advice for Clinicians Treating IPF
EP: 6.Current Standard of Care in IPF
EP: 7.Therapeutic Response and Disease Progression
EP: 8.Key Considerations for Selecting IPF Treatment
EP: 9.Economic Impact of IPF
EP: 10.Unmet Needs in IPF Landscape
EP: 11.Overview of Idiopathic Pulmonary Fibrosis (IPF)
EP: 12.Impact of IPF on Quality of Life and Financial Considerations
EP: 13.Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection
EP: 14.Clinical Presentation and Risk Factors
EP: 15.Impact of Comorbidities on IPF Management
EP: 16.Overcoming Treatment Barriers: Strategies for Success
EP: 17.Impact of Treatment Delays on Patient Outcomes
Video content above is prompted by the following:
- What is the impact of IPF on patient productivity and how does this contribute to the overall economic burden of the disease?
Historical Redlining Increases Mortality Risk Among Young Patients With Cancer
January 27th 2025Young patients with cancer residing in historically redlined areas face a significantly higher risk of mortality, demonstrating that structural racism contributes to disparities in survival outcomes.
Read More
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
January 27th 2025The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Read More
